Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO

This article has no abstract
Epistemonikos ID: 644dd885c3ce6b87cb518249771c9784237849f5
First added on: Feb 13, 2025